Asahi Intecc Co., Ltd.

DB:6XT Stock Report

Market Cap: €4.6b

Asahi Intecc Valuation

Is 6XT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6XT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6XT (€16.8) is trading above our estimate of fair value (€10.83)

Significantly Below Fair Value: 6XT is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6XT?

Key metric: As 6XT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 6XT. This is calculated by dividing 6XT's market cap by their current earnings.
What is 6XT's PE Ratio?
PE Ratio44.7x
EarningsJP¥16.52b
Market CapJP¥737.46b

Price to Earnings Ratio vs Peers

How does 6XT's PE Ratio compare to its peers?

The above table shows the PE ratio for 6XT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average23x
PHH2 Paul Hartmann
12.5xn/a€745.9m
AFX Carl Zeiss Meditec
25.8x16.3%€5.2b
EUZ Eckert & Ziegler
25.6x5.9%€918.9m
SYAB SYNLAB
28x-11.4%€2.5b
6XT Asahi Intecc
44.7x12.2%€737.5b

Price-To-Earnings vs Peers: 6XT is expensive based on its Price-To-Earnings Ratio (44.7x) compared to the peer average (23x).

Price to Earnings Ratio vs Industry

How does 6XT's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
6XT 44.7xIndustry Avg. 29.8xNo. of Companies8PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 6XT is expensive based on its Price-To-Earnings Ratio (44.7x) compared to the European Medical Equipment industry average (29.7x).

Price to Earnings Ratio vs Fair Ratio

What is 6XT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6XT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio44.7x
Fair PE Ratio24.4x

Price-To-Earnings vs Fair Ratio: 6XT is expensive based on its Price-To-Earnings Ratio (44.7x) compared to the estimated Fair Price-To-Earnings Ratio (24.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 6XT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€16.80
€20.72
+23.4%
11.4%€25.96€16.07n/a15
Nov ’25€14.40
€20.36
+41.4%
13.4%€24.90€15.19n/a14
Oct ’25€15.50
€20.36
+31.3%
13.4%€24.90€15.19n/a14
Sep ’25€16.40
€20.00
+21.9%
13.3%€24.92€15.20n/a14
Aug ’25€13.70
€18.80
+37.2%
14.9%€23.16€12.86n/a13
Jul ’25€12.30
€19.21
+56.2%
14.6%€22.38€13.07n/a13
Jun ’25€13.10
€19.25
+46.9%
14.2%€22.31€13.03n/a14
May ’25€13.60
€20.67
+52.0%
10.6%€23.14€14.61n/a14
Apr ’25€15.90
€20.95
+31.8%
7.9%€23.25€17.13n/a14
Mar ’25€18.90
€21.00
+11.1%
7.9%€23.45€17.28n/a13
Feb ’25€17.70
€21.41
+21.0%
9.0%€24.05€16.77n/a13
Jan ’25€18.10
€21.41
+18.3%
9.0%€24.05€16.77n/a13
Dec ’24€17.20
€20.66
+20.1%
9.1%€23.02€16.05n/a14
Nov ’24€15.60
€20.96
+34.4%
9.6%€23.38€15.80€14.4013
Oct ’24€16.80
€21.51
+28.0%
6.9%€23.35€17.67€15.5010
Sep ’24€18.20
€20.68
+13.6%
9.4%€22.71€16.40€16.4010
Aug ’24€18.50
€21.12
+14.2%
10.0%€23.01€16.62€13.7010
Jul ’24€17.60
€21.24
+20.7%
11.5%€23.78€17.18€12.3010
Jun ’24€18.00
€20.68
+14.9%
12.5%€23.87€16.91€13.1011
May ’24€16.20
€20.30
+25.3%
13.0%€23.79€15.64€13.6011
Apr ’24€15.80
€20.59
+30.3%
12.5%€24.19€15.89€15.9012
Mar ’24€15.20
€21.02
+38.3%
12.6%€24.49€16.10€18.9012
Feb ’24€15.60
€21.40
+37.2%
11.8%€24.80€16.30€17.7012
Jan ’24€15.10
€21.33
+41.2%
14.1%€27.78€15.97€18.1012
Dec ’23€17.50
€20.93
+19.6%
14.4%€27.48€15.80€17.2012
Nov ’23€16.90
€20.96
+24.0%
14.0%€27.67€15.91€15.6012

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.6b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.53

7D

1.0%

1Y

-34.2%

LNA Santé

€234.2m

Engages in the management and operation of health establishments.

2N3

€22.30

7D

-4.9%

1Y

16.8%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%